These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18570964)

  • 21. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
    Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
    Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.
    Marzi A; Halfmann P; Hill-Batorski L; Feldmann F; Shupert WL; Neumann G; Feldmann H; Kawaoka Y
    Science; 2015 Apr; 348(6233):439-42. PubMed ID: 25814063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
    Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.
    Anguiano-Zarate SS; Matchett WE; Nehete PN; Sastry JK; Marzi A; Barry MA
    J Infect Dis; 2018 Nov; 218(12):1883-1889. PubMed ID: 29982595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
    Geisbert TW; Bailey M; Hensley L; Asiedu C; Geisbert J; Stanley D; Honko A; Johnson J; Mulangu S; Pau MG; Custers J; Vellinga J; Hendriks J; Jahrling P; Roederer M; Goudsmit J; Koup R; Sullivan NJ
    J Virol; 2011 May; 85(9):4222-33. PubMed ID: 21325402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
    Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
    Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
    Xie L; Zai J; Yi K; Li Y
    Vaccine; 2019 May; 37(25):3335-3342. PubMed ID: 31076161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the development of vaccines for Ebola virus disease.
    Ohimain EI
    Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Single-Dose Intranasal Combination Panebolavirus Vaccine.
    Malherbe DC; Kimble JB; Atyeo C; Fischinger S; Meyer M; Cody SG; Hyde M; Alter G; Bukreyev A
    J Infect Dis; 2023 Nov; 228(Suppl 7):S648-S659. PubMed ID: 37469133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
    Meyer M; Yoshida A; Ramanathan P; Saphire EO; Collins PL; Crowe JE; Samal S; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1816-1829. PubMed ID: 30110638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.
    Marzi A; Murphy AA; Feldmann F; Parkins CJ; Haddock E; Hanley PW; Emery MJ; Engelmann F; Messaoudi I; Feldmann H; Jarvis MA
    Sci Rep; 2016 Feb; 6():21674. PubMed ID: 26876974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.
    Reynard O; Jacquot F; Evanno G; Mai HL; Salama A; Martinet B; Duvaux O; Bach JM; Conchon S; Judor JP; Perota A; Lagutina I; Duchi R; Lazzari G; Le Berre L; Perreault H; Lheriteau E; Raoul H; Volchkov V; Galli C; Soulillou JP
    PLoS One; 2016; 11(6):e0156775. PubMed ID: 27280712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.